TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants with suicidal behaviour
Endpoint domain: Adverse events/effects
Primary endpoint: Average percent change in PNIF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: degree of local anaesthetics spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective ratings and preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Chronic Low Back Pain (CLBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete enteroscopy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Performance of the Wells Clinical prediction score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Harris Hip Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-max: Concentration of the Peak in the Plasma Concentration Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC-(0-inf): Area under the plasma concentration versus time curve extrapolated to infinity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Removal of Study Stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the incisal inclinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hCAP18 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of serum lipids, lipoproteins, and total apolipoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of erosions and ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement on Cardiometabolic Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Blood Test Variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Adherence to the Proposed Dietary Pattern
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vitiligo Area and Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale (mRS) 0-3 vs mRS 4-6
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Chest tube therapy duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued Study Treatment Due to An Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-Emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Fugl-Meyer (FM) motor scale, short form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of HTD for fever measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to gluten-free or wheat-free diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: success rates of root canal treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of AKI requiring dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine Urea Nitrogen (UUN) for Nitrogen Balance (NB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Readmission in hospital within 30 days of discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Successful Weaning off a Proton Pump Inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Severe Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Clinical Laboratory Values
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change of Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change of Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Periprocedural infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CBER ID50 skin test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Constant-Murley Score (CM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EuroQol-5D-3L (European Quality of Life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sustained Production of Hemoglobin A (HbAT87Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Brief Pain Inventory (BPI) Severity Score at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Brief Pain Inventory (BPI) Interference Score at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score: Clinician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death or stroke in downstream territory
Endpoint domain: Mortality/survival
Primary endpoint: Rate of aneurysm occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of grade≥2 radiation pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Mean glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inattention/Overactivity ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in liver glycogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in Spike-wave Fraction of the EEG Recording Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with clinical and microbiological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TCD-blood Flow Velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pharmacokinetics of total telaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient Mask Preference Quantitative
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Survey Scores Evaluating Surgeon Communication Skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Survey Scores Describing Trust in the Surgeon
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient and Written Examination Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants with neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of a behavioral problem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sonographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous thromboembolisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants Using a Triptan for Migraine Attacks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Continuing Triptan Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Main Reason for Stopping Triptan Use
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent rate of ischemic stroke and/or transient ischemic attack
Endpoint domain: Mortality/survival
Primary endpoint: Change in pain in the low back and legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Treatment-related fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Coordination of Care efforts evaluation score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: minimum effective volume of ropivacaine providing a successful infraclavicular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survival from cardiac arrest to hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Time spent within target glucose range (preoperative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent within target glucose range (postoperative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in BMD at the Lumber spine, hip, fore-arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distal migration of the femoral prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of MII oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ApoB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in MDS-UPDRS Part III Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptoms of foot fungus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Numeric Rating Scale (NRS) Pain Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical symptoms after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of functional worsening of the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of New-onset Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamic Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin conductance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Antigen-specific Interferon-Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to Public Health Service Guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with cardiovascular death after 5-year follow up
Endpoint domain: Mortality/survival
Primary endpoint: adherence to topical medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Working Memory (% correct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Response Time (milliseconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Short Term Memory (# correct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Mood (change in Likert scale score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Attention (% accuracy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Executive Function (# correct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: EBOV-specific IgG antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of responder patients to prone position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative nausea and vomiting (PONV)
Endpoint domain: Adverse events/effects
Primary endpoint: 7-day Point Prevalence Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structured objective clinical evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcutaneous carbon dioxide partial pressure variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of a positive PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiovascular risk as determined by UKPDS Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolic outcomes (HgbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic outcomes (LDL Cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic Outcomes (Systolic Blood Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Graded Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Stent length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Japanese Orthopedic Association score (JOA-29)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: novel PRO instrument
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in ECBI (Eyberg Child Behavior Checklist)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in CBCL (Child Behaviour Checklist) Externalizing scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long term change in ECBI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long term change in CBCL Externalizing scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: area of Schlemm's canal and trabecular meshwork
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage Change in Total Toronto Western Spasmodic Torticollis Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of PCCE, MREC and US for the diagnosis of CD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on Root Means Square
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on muscle tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Facts about Osteoarthritis section of the Decision Quality Instrument - Knee Osteoarthritis (DQI-KOA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Decision Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Liver histology score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer assessment of physical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test Box and Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: Visual evaluation of skin condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in writing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduced amount of drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Haptoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Hemoglobin (Hb) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Interleukins concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of de novo dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vasovagal reaction
Endpoint domain: Adverse events/effects
Primary endpoint: accuracy of verticality perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Major and minor but clinically relevant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Eye Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Adverse Events (AEs) Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Best PSA Response at Day 85
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment Emergent Adverse Events by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Spinal oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced at Least One Treatment-emergent Serious AE (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in HCV RNA From Baseline on Day 8 Following Uprifosbuvir 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cutaneous Tolerance Scores: Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous Tolerance Scores: Dryness/Scaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous Tolerance Scores: Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous Tolerance Scores: Burning/Stinging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous Tolerance Scores: Itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Length of visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean PA burst pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in asthma control test (ACT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score on the FACT-Cog-addendum
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in score on the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in neural function measured by fMRI BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in A1C Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in UDI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Colony-Forming Units (CFU)/ml from peritoneal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in safety laboratory parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Overall score of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Reporting Questionnaire 20 (SRQ-20)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in HIV-1 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Proinsulin/Insulin (PI/I) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Visual Field defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change of the scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time of Cmax after subcutaneous administration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve during a drug dosing interval (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes